Common visual problems: Symptoms and treatment, part II

Annals of Long-Term Care

Volumn 13, Issue 9, 2005, Pages 41-46

  Michelson, Paul E ^a  

^a SCRIPPS MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ARTIFICIAL TEAR; ASCORBIC ACID; BETA CAROTENE; COPPER; COPPER OXIDE; CYCLOSPORIN; GROWTH FACTOR; MINERAL; UNCLASSIFIED DRUG; VITAMIN; ZINC OXIDE;

BLINDNESS; DIABETIC RETINOPATHY; DRY EYE; EARLY DIAGNOSIS; ELDERLY CARE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INCIDENCE; LASER COAGULATION; LASER SURGERY; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHOTODYNAMIC THERAPY; PHOTORECEPTOR; PRIMARY MEDICAL CARE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK REDUCTION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 25444457737     PISSN: 15247929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Munoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol 2000;118(6):819-825.
2. West SK, Munoz B, Rubin GS, et al. Function and visual impairment in a population-based study of older adults. The SEE (Salisbury Eye Evaluation) Project. Invest Ophthalmol Vis Sci 1997;38(1):72-82.
3. Robilotto R, Zaidi Q. Limits of lightness identification for real objects under natural viewing conditions. J Vis 2004;15;4(9):779-797.
4. Puell MC, Palomo C, Sanchez-Ramos C, Villena C. Normal values for photopic and mesopic letter contrast sensitivity. J Refract Surg 2004;20(5):484-488.
5. Pesudovs K, Marsack JD, Donnelly WJ III, et al. Measuring visual acuity: Mesopic or photopic conditions, and high or low contrast letters? J Refract Surg 2004;20(5):S508-S514.
6. Stevenson MR, Hart PM, Montgomery AM, et al. Reduced vision in older adults with age related macular degeneration interferes with ability to care for self and impairs role as carer. Br J Ophthalmol 2004;88(9):1125-1130.
7. de Boer MR, Pluijm SM, Lips P, et al. Different aspects of visual impairment as risk factors for falls and fractures in older men and women. J Bone Miner Res 2004;19(9):1539-1547. Epub 2004 May 10.
8. Turano KA, Broman AT, Bandeen-Roche K, et al; SEE Project Team. Association of visual field loss and mobility performance in older adults: Salisbury Eye Evaluation Study. Optom Vis Sci 2004;81(5):298-307.
9. Klein BE, Klein R, Knudtson MD, Lee KE. Relationship of measures of frailty to visual function: The Beaver Dam Eye-Study. Trans Am Ophthalmol Soc 2003; 101:191-199.
10. West CG, Gildengorin G, Haegerstrom-Portnoy G, et al. Vision and driving self-restriction in older adults. J Am Geriatr Soc 2003;51(10):1348-1355.
11. de Winter LJ, Hoyng CB, Froeling PG, et al. Prevalence of remediable disability due to low vision among institutionalised elderly people. Gerontology 2004;50 (2):96-101.
12. Cox A, Blaikie A, MacEwen CJ, et al. Visual impairment in elderly patients with hip fracture: Causes and associations. Eye 2004 Aug 27; [Epub ahead of print].
13. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137(3):486-495.
14. Arnold J, Sarks S. Age related macular degeneration. Clin Evid 2004;(11): 819-834.
15. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004;44(4):17-39.
16. Verteporforin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: An update. Retina 2005;25(2):119-134.
17. Michels S, Schmidt-Erfurth U. Photodynamic therapy with verteporfin: A new treatment in ophthalmology. Semin Ophtalmol 2001;16(4):201-206.
18. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 2003;110(5):979-986.
19. Bressler NM, Bressler SB, Congdon NG, et al; Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS Report No. 11. Arch Ophthalmol 2003;121(11): 1621-1624.
20. Jampol LM. AREDS: Two years later. Arch Ophthalmol 2003;121(11): 1634-1636.
21. Blodi BA. Nutritional supplements in the prevention of age-related macular degeneration. Insight 2004;29(1):15-18.
22. Arora S, Musadiq M, Mukherji S, Yang YC. Eye nutrient products for age-related macular degeneration: What do they contain? Eye 2004;18(5):470-473.
23. Ribaya-Mercado JD, Blumberg JB. Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr 2004;23(6 Suppl):567S-587S.
24. McBee WL, Lindblad AS, Ferris FL III. Who should receive oral supplement treatment for age-related macular degeneration? Curr Opin Ophthalmol 2003;14(3):159-162.
25. Chang CW, Chu G, Hinz BJ, Greve MD. Current use of dietary supplementation in patients with age-related macular degeneration. Can J Ophthalmol 2003;38(1):27-32.
26. Comer GM, Gulla TA, Criswell MH, Tolentino M. Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 2004;21(15):967-992.
27. Centers for Disease Control and Prevention (CDC). Prevalence of visual impairment and selected eye diseases among persons aged ≥ 50 years with and without diabetes: United States, 2002. MMWR Morb Mortal Wkly Rep 2004;53(45):1069-1071.
28. Harding S, Garvican L, Talbot J. The impact of national diabetic retinopathy screening on ophthalmology: The need for urgent planning. Eye 2004; [Epub ahead of print].
29. Harding S. Diabetic retinopathy. Clin Evid 2003;(9):718-728.
30. Walker R. Diabetic retinopathy: Protecting the vision of people with diabetes. Br J Community Nurs 2004;9(12):545-547.
31. Harding S. Diabetic retinopathy. Clin Evid 2004;(11):848-859.
32. Chew EY, Ferris FL III, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: The early treatment diabetic retinopathy follow-up study. Ophthalmology 2003;110(9):1683-1689.
33. Tranos PG, Topouzis F, Stongos NT, et al. Effect of laser photocoagulation treatment for diabetic macular oedemo on patient's vision-related quality of life. Curr Eye Res 2004;29(1):41-49.
34. Shah KB, Han DP. Proliferative diabetic retinopathy. Int Ophthalmol Clin 2004; 44(4):69-84.
35. Michels RG. Proliferative diabetic retinopathy: Pathophysiology of extraretinal complications and principles of vitreous surgery. Retina 1981;1(1):1-17.
36. Klein R, Zinman B, Gardiner R, et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: The Renin-Angiotensin System Study. Diabetes 2005;54(2):527-533.
37. Dalzell MD. Dry eye: Prevalence, utilization, and economic implications. Manag Care 2003;12(12 Suppl):9-13.
38. Moss SE, Klein R, Klein BE. Incidence of dry eye in an older population. Arch Ophthalmol 2004;122(3):369-373.
39. Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: A population-based assessment. Arch Intern Med 1999;159(12): 1359-1363.
40. Eichenbaum JW, Burton WB, Eichenbaum GM, Mulvihill M. The prevalence of eye disease in nursing home and non-nursing home geriatric populations. Arch Gerontol Geriatr 1999;28(3):191-204.
41. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136(2):318-326.
42. Bandeen-Roche K, Munoz B, Tielsch JM, et al. Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci 1997;38(12): 2469-2475.
43. Pflugfelder SC. Hormonal deficiencies and dry eye. Arch Ophthalmol 2004; 122(2):273-274.
44. Wilson SE. Inflammation: A unifying theory far the origin of dry eye syndrome. Manag Care 2003;12(12 Suppl):14-19.
45. Sheppard JD. Dry eye moves beyond palliative therapy. Manag Care 2003; 12(12 Suppl):6-8.
46. Perry HD, Donnenfeld ED. Topical 0.05% cyclosparin in the treatment of dry eye. Expert Opin Pharmacother 2004;5(10):2099-2107.
47. Brown MM, Brown GC. Utility assessment and dry eye disease. Ophthalmology 2004;111(4):852-853.
48. Whitcher JP. The treatment of dry eyes. Br J Ophthalmol 2004;88(5):603-604.
49. Sheppard JD. Guidelines for the treatment of chronic dry eye disease. Manag Care 2003;12(12 Suppl):20-25.
50. Dana MR, Sullivan DA, Parke AL. Toward optimal health: The experts discuss dry eye syndrome. Interview by Jodi Godfrey Meisler. J Womens Health Gend Based Med 2001;10(8):725-729.
51. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 2004;15(4):299-304.